Livzon Pharmaceutical Group Inc. (1513.HK)
HKD 26.9
(-0.37%)
HKD 26.9
(-0.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.18 Billion CNY | -5.77% |
| 2022 | -6.79 Billion CNY | -5.28% |
| 2021 | -6.45 Billion CNY | 19.59% |
| 2020 | -8.02 Billion CNY | -7.06% |
| 2019 | -7.49 Billion CNY | -5.75% |
| 2018 | -7.08 Billion CNY | 4.42% |
| 2017 | -7.41 Billion CNY | -259.79% |
| 2016 | -2.06 Billion CNY | -1300.06% |
| 2015 | -147.19 Million CNY | -215.8% |
| 2014 | 127.11 Million CNY | -54.66% |
| 2013 | 280.34 Million CNY | 140.98% |
| 2012 | -684.06 Million CNY | 42.75% |
| 2011 | -1.19 Billion CNY | -130.09% |
| 2010 | -519.27 Million CNY | -86.24% |
| 2009 | -278.81 Million CNY | -404.29% |
| 2008 | 91.63 Million CNY | -56.04% |
| 2007 | 208.44 Million CNY | -48.85% |
| 2006 | 407.53 Million CNY | -12.41% |
| 2005 | 465.3 Million CNY | 98.06% |
| 2004 | 234.93 Million CNY | 151.46% |
| 2003 | 93.42 Million CNY | 330.06% |
| 2002 | -40.6 Million CNY | -158.54% |
| 2001 | 69.36 Million CNY | -39.3% |
| 2000 | 114.28 Million CNY | 171.19% |
| 1999 | 42.14 Million CNY | -75.83% |
| 1998 | 174.38 Million CNY | 51.02% |
| 1997 | 115.47 Million CNY | -48.42% |
| 1996 | 223.85 Million CNY | 36.5% |
| 1995 | 164 Million CNY | 178.08% |
| 1994 | 58.97 Million CNY | 10.43% |
| 1993 | 53.4 Million CNY | -63.87% |
| 1992 | 147.82 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -7.57 Billion CNY | -5.49% |
| 2024 Q3 | -8.27 Billion CNY | -10.77% |
| 2024 Q2 | -7.45 Billion CNY | 1.57% |
| 2023 Q2 | -6.57 Billion CNY | 3.51% |
| 2023 FY | -7.18 Billion CNY | -5.77% |
| 2023 Q4 | -7.18 Billion CNY | -13.23% |
| 2023 Q1 | -6.81 Billion CNY | -0.39% |
| 2023 Q3 | -6.34 Billion CNY | 3.57% |
| 2022 Q2 | -5.94 Billion CNY | 14.33% |
| 2022 Q3 | -6.11 Billion CNY | -2.95% |
| 2022 Q4 | -6.79 Billion CNY | -11.06% |
| 2022 FY | -6.79 Billion CNY | -5.28% |
| 2022 Q1 | -6.93 Billion CNY | -7.48% |
| 2021 Q4 | -6.45 Billion CNY | 0.11% |
| 2021 Q3 | -6.45 Billion CNY | -4.74% |
| 2021 FY | -6.45 Billion CNY | 19.59% |
| 2021 Q2 | -6.16 Billion CNY | 24.39% |
| 2021 Q1 | -8.15 Billion CNY | -1.66% |
| 2020 Q2 | -7.01 Billion CNY | 9.25% |
| 2020 Q1 | -7.72 Billion CNY | -3.08% |
| 2020 FY | -8.02 Billion CNY | -7.06% |
| 2020 Q3 | -7.56 Billion CNY | -7.92% |
| 2020 Q4 | -8.02 Billion CNY | -6.06% |
| 2019 FY | -7.49 Billion CNY | -5.75% |
| 2019 Q4 | -7.49 Billion CNY | -3.84% |
| 2019 Q3 | -7.21 Billion CNY | 7.09% |
| 2019 Q2 | -7.76 Billion CNY | -6.02% |
| 2019 Q1 | -7.32 Billion CNY | -3.38% |
| 2018 Q3 | -6.65 Billion CNY | -8.48% |
| 2018 Q4 | -7.08 Billion CNY | -6.56% |
| 2018 FY | -7.08 Billion CNY | 4.42% |
| 2018 Q1 | -7.3 Billion CNY | 1.54% |
| 2018 Q2 | -6.13 Billion CNY | 16.02% |
| 2017 Q2 | -6.8 Billion CNY | -124.02% |
| 2017 Q4 | -7.41 Billion CNY | -6.2% |
| 2017 Q3 | -6.98 Billion CNY | -2.63% |
| 2017 Q1 | -3.03 Billion CNY | -47.36% |
| 2017 FY | -7.41 Billion CNY | -259.79% |
| 2016 FY | -2.06 Billion CNY | -1300.06% |
| 2016 Q4 | -2.06 Billion CNY | 10.73% |
| 2016 Q3 | -2.3 Billion CNY | -5094.65% |
| 2016 Q2 | -44.44 Million CNY | 79.88% |
| 2016 Q1 | -220.88 Million CNY | -50.06% |
| 2015 Q3 | 160.17 Million CNY | -50.63% |
| 2015 FY | -147.19 Million CNY | -215.8% |
| 2015 Q1 | -22.77 Million CNY | -117.92% |
| 2015 Q2 | 324.44 Million CNY | 1524.44% |
| 2015 Q4 | -147.19 Million CNY | -191.9% |
| 2014 Q3 | 327.38 Million CNY | -31.37% |
| 2014 Q1 | 274.88 Million CNY | -1.95% |
| 2014 Q2 | 477.05 Million CNY | 73.55% |
| 2014 FY | 127.11 Million CNY | -54.66% |
| 2014 Q4 | 127.11 Million CNY | -61.17% |
| 2013 Q2 | -409.37 Million CNY | 22.11% |
| 2013 FY | 280.34 Million CNY | 140.98% |
| 2013 Q4 | 280.34 Million CNY | 60.05% |
| 2013 Q1 | -525.57 Million CNY | 23.17% |
| 2013 Q3 | 175.15 Million CNY | 142.79% |
| 2012 Q4 | -684.06 Million CNY | 11.85% |
| 2012 FY | -684.06 Million CNY | 42.75% |
| 2012 Q3 | -776.03 Million CNY | -48.62% |
| 2012 Q1 | -894.81 Million CNY | 25.11% |
| 2012 Q2 | -522.17 Million CNY | 41.65% |
| 2011 FY | -1.19 Billion CNY | -130.09% |
| 2011 Q4 | -1.19 Billion CNY | -19.29% |
| 2011 Q3 | -1 Billion CNY | 5.76% |
| 2011 Q2 | -1.06 Billion CNY | -79.72% |
| 2011 Q1 | -591.37 Million CNY | -13.89% |
| 2010 Q1 | -385.36 Million CNY | -38.21% |
| 2010 Q4 | -519.27 Million CNY | -37.56% |
| 2010 FY | -519.27 Million CNY | -86.24% |
| 2010 Q3 | -377.49 Million CNY | -6.68% |
| 2010 Q2 | -353.84 Million CNY | 8.18% |
| 2009 Q4 | -278.81 Million CNY | -48.77% |
| 2009 Q1 | -158.24 Million CNY | -272.7% |
| 2009 Q2 | -136.91 Million CNY | 13.48% |
| 2009 Q3 | -187.41 Million CNY | -36.88% |
| 2009 FY | -278.81 Million CNY | -404.29% |
| 2008 Q1 | 172.35 Million CNY | -17.31% |
| 2008 Q2 | 239.33 Million CNY | 38.86% |
| 2008 FY | 91.63 Million CNY | -56.04% |
| 2008 Q3 | 211.62 Million CNY | -11.58% |
| 2008 Q4 | 91.63 Million CNY | -56.7% |
| 2007 Q2 | 352.72 Million CNY | 1.72% |
| 2007 Q4 | 208.44 Million CNY | -10.74% |
| 2007 FY | 208.44 Million CNY | -48.85% |
| 2007 Q1 | 346.74 Million CNY | -14.92% |
| 2007 Q3 | 233.51 Million CNY | -33.8% |
| 2006 Q3 | 637.27 Million CNY | -7.32% |
| 2006 FY | 407.53 Million CNY | -12.41% |
| 2006 Q4 | 407.53 Million CNY | -36.05% |
| 2006 Q2 | 687.56 Million CNY | 34.75% |
| 2006 Q1 | 510.26 Million CNY | 9.66% |
| 2005 Q4 | 465.3 Million CNY | 5.7% |
| 2005 Q3 | 440.2 Million CNY | 32.44% |
| 2005 Q2 | 332.38 Million CNY | 19.36% |
| 2005 Q1 | 278.46 Million CNY | 18.53% |
| 2005 FY | 465.3 Million CNY | 98.06% |
| 2004 Q4 | 234.93 Million CNY | 23.73% |
| 2004 Q3 | 189.87 Million CNY | 0.68% |
| 2004 Q2 | 188.58 Million CNY | 44.96% |
| 2004 Q1 | 130.09 Million CNY | 39.25% |
| 2004 FY | 234.93 Million CNY | 151.46% |
| 2003 Q2 | -154.04 Million CNY | -66.64% |
| 2003 Q1 | -92.44 Million CNY | -127.64% |
| 2003 FY | 93.42 Million CNY | 330.06% |
| 2003 Q4 | 93.42 Million CNY | 151.67% |
| 2003 Q3 | -180.82 Million CNY | -17.38% |
| 2002 Q3 | 25.48 Million CNY | -83.68% |
| 2002 Q1 | 116.84 Million CNY | 68.44% |
| 2002 FY | -40.6 Million CNY | -158.54% |
| 2002 Q2 | 156.15 Million CNY | 33.65% |
| 2002 Q4 | -40.6 Million CNY | -259.33% |
| 2001 Q4 | 69.36 Million CNY | 0.0% |
| 2001 Q2 | 66.11 Million CNY | 0.0% |
| 2001 FY | 69.36 Million CNY | -39.3% |
| 2000 Q4 | 114.28 Million CNY | 0.0% |
| 2000 Q2 | 70.42 Million CNY | 0.0% |
| 2000 FY | 114.28 Million CNY | 171.19% |
| 1999 FY | 42.14 Million CNY | -75.83% |
| 1999 Q2 | 138.18 Million CNY | 0.0% |
| 1999 Q4 | 42.14 Million CNY | 0.0% |
| 1998 Q4 | 174.38 Million CNY | 0.0% |
| 1998 Q2 | 182.53 Million CNY | 0.0% |
| 1998 FY | 174.38 Million CNY | 51.02% |
| 1997 Q4 | 115.47 Million CNY | 0.0% |
| 1997 FY | 115.47 Million CNY | -48.42% |
| 1997 Q2 | - CNY | 0.0% |
| 1996 Q2 | - CNY | 0.0% |
| 1996 Q4 | 223.85 Million CNY | 0.0% |
| 1996 FY | 223.85 Million CNY | 36.5% |
| 1995 Q4 | 164 Million CNY | 0.0% |
| 1995 FY | 164 Million CNY | 178.08% |
| 1995 Q2 | - CNY | 0.0% |
| 1994 Q4 | 58.97 Million CNY | 0.0% |
| 1994 Q2 | - CNY | 0.0% |
| 1994 FY | 58.97 Million CNY | 10.43% |
| 1993 FY | 53.4 Million CNY | -63.87% |
| 1992 FY | 147.82 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | -2677.019% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 453.579% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 120965.257% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 2482.545% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | -37636.269% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 23313.878% |
| Essex Bio-Technology Limited | -219.22 Million HKD | -3177.044% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 2904.544% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 2002.861% |
| SSY Group Limited | 1.71 Billion HKD | 519.267% |
| JBM (Healthcare) Limited | -7.39 Million HKD | -96997.322% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 2229.027% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 114.092% |